POMSnet Aquila MES software major release delivers the best of customer requests. Combining 60+ new features across the electronic batch record software suite, POMSnet Aquila MES sets a new bar for MES software.Read More
As advocates of diverse and inclusive clinical trials, patient engagement agency COUCH Health is calling on the industry take action to make clinical research more inclusive and representative of all populations. Demand Diversity has launched with the aim to raise awareness of the lack of diversity in clinical research and make change happen.Read More
Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled "Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial", the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208Read More
This is the first time a Cannabinoid-Containing Complex Mixture (CCCM™) has been awarded a U.S. patent, which thereby validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolioRead More
Video based On-line Regulatory Training ComplianceQuest's End-to-End Enterprise Document and Learning Management SolutionsRead More
A new type of sensor device from the German health technology company Digital Diagnostics AG can be used for immediate tests for the new SARS coronavirus. In comparison to currently available rapid tests, the SARS-CoV-2 MEMS 5 Minute Test™ directly detects the virus over the entire course of the infection and can be read immediately, without the need for a laboratory.Read More
Unique Testing Protocol From Precision Diagnostics Company Unlocks One Million Tests Per Day: The BillionToOne COVID-19 test uses different sets of instruments and chemicals from existing COVID-19 tests, enabling labs to unlock a new set of unused capacity.
GBS Global Biopharma, Inc., the Canadian holding of GB Sciences, signed an Amendment to their Agreement with the National Research Council of Canada (NRC) to include valuable testing of Mechanism of Action for its Parkinson's Disease (PD) Formulations to strengthen their Investigational New Drug (IND) Application to the US FDA in preparation for human trials addressing a $52 billion market in the US alone.Read More